Preferred Label : Anti-PTK7/Exatecan Antibody-drug Conjugate DAY301;
NCIt synonyms : Anti-PTK7/Exatecan ADC DAY301; Anti-PTK7 Antibody-drug Conjugate DAY301; Anti-PTK7 ADC DAY301;
NCIt definition : An antibody-drug conjugate (ADC) composed of Ab13, an antibody directed against human
inactive tyrosine-protein kinase 7 (protein tyrosine kinase 7; PTK7) conjugated, via
the hydrophilic self-immolative moiety T1000, to the cytotoxic agent and DNA topoisomerase
I inhibitor exatecan, with potential antineoplastic activity. Upon administration
of anti-PTK7/exatecan ADC DAY301, the anti-PTK7 antibody Ab13 targets and binds to
PTK7 expressed on tumor cells. Upon binding, internalization and cleavage, exatecan
is released and inhibits DNA topoisomerase I activity, thereby inhibiting DNA replication
and resulting in DNA damage, cell cycle arrest and apoptosis in tumor cells overexpressing
PTK7. In addition, this may cause a bystander effect, thereby further killing PTK7-expressing
tumor cells. PTK7, a tumor-associated antigen (TAA), is overexpressed on a variety
of cancer cells with limited expression in normal tissues. It is an integral player
in cancer cell stemness and tumor progression. The hydrophilic moiety T1000 is used
to overcome the hydrophobicity of conjugated exatecan.;
Molecule name : MTX 13; MTX-13; DAY 301; DAY-301;
Origin ID : C216980;
concept_is_in_subset
- has_target
